59 related articles for article (PubMed ID: 38455039)
21. Clinical significance of CD200 expression in newly diagnosed multiple myeloma patients and dynamic changing during treatment.
Shi Q; Wu C; Han W; Zhao S; Wu Y; Jin Y; Qu X; Li J; Zhang R; Chen L
Leuk Lymphoma; 2021 Mar; 62(3):709-715. PubMed ID: 33108911
[TBL] [Abstract][Full Text] [Related]
22. The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses.
Labani-Motlagh A; Ashja-Mahdavi M; Loskog A
Front Immunol; 2020; 11():940. PubMed ID: 32499786
[TBL] [Abstract][Full Text] [Related]
23. CD200 Checkpoint Reversal: A Novel Approach to Immunotherapy.
Xiong Z; Ampudia Mesias E; Pluhar GE; Rathe SK; Largaespada DA; Sham YY; Moertel CL; Olin MR
Clin Cancer Res; 2020 Jan; 26(1):232-241. PubMed ID: 31624103
[TBL] [Abstract][Full Text] [Related]
24. PDCD1 and PDCD1LG1 polymorphisms affect the susceptibility to multiple myeloma.
Kasamatsu T; Awata M; Ishihara R; Murakami Y; Gotoh N; Matsumoto M; Sawamura M; Yokohama A; Handa H; Tsukamoto N; Saitoh T; Murakami H
Clin Exp Med; 2020 Feb; 20(1):51-62. PubMed ID: 31620907
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200.
Mahadevan D; Lanasa MC; Farber C; Pandey M; Whelden M; Faas SJ; Ulery T; Kukreja A; Li L; Bedrosian CL; Zhang X; Heffner LT
J Immunother Cancer; 2019 Aug; 7(1):227. PubMed ID: 31443741
[TBL] [Abstract][Full Text] [Related]
26. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.
Usmani SZ; Schjesvold F; Oriol A; Karlin L; Cavo M; Rifkin RM; Yimer HA; LeBlanc R; Takezako N; McCroskey RD; Lim ABM; Suzuki K; Kosugi H; Grigoriadis G; Avivi I; Facon T; Jagannath S; Lonial S; Ghori RU; Farooqui MZH; Marinello P; San-Miguel J;
Lancet Haematol; 2019 Sep; 6(9):e448-e458. PubMed ID: 31327689
[TBL] [Abstract][Full Text] [Related]
27. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Mateos MV; Blacklock H; Schjesvold F; Oriol A; Simpson D; George A; Goldschmidt H; Larocca A; Chanan-Khan A; Sherbenou D; Avivi I; Benyamini N; Iida S; Matsumoto M; Suzuki K; Ribrag V; Usmani SZ; Jagannath S; Ocio EM; Rodriguez-Otero P; San Miguel J; Kher U; Farooqui M; Liao J; Marinello P; Lonial S;
Lancet Haematol; 2019 Sep; 6(9):e459-e469. PubMed ID: 31327687
[TBL] [Abstract][Full Text] [Related]
28. Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma.
Badros AZ; Ma N; Rapoport AP; Lederer E; Lesokhin AM
Blood Adv; 2019 Jun; 3(11):1658-1660. PubMed ID: 31167817
[No Abstract] [Full Text] [Related]
29. Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade.
Minnie SA; Kuns RD; Gartlan KH; Zhang P; Wilkinson AN; Samson L; Guillerey C; Engwerda C; MacDonald KPA; Smyth MJ; Markey KA; Vuckovic S; Hill GR
Blood; 2018 Oct; 132(16):1675-1688. PubMed ID: 30154111
[TBL] [Abstract][Full Text] [Related]
30. TIGIT immune checkpoint blockade restores CD8
Guillerey C; Harjunpää H; Carrié N; Kassem S; Teo T; Miles K; Krumeich S; Weulersse M; Cuisinier M; Stannard K; Yu Y; Minnie SA; Hill GR; Dougall WC; Avet-Loiseau H; Teng MWL; Nakamura K; Martinet L; Smyth MJ
Blood; 2018 Oct; 132(16):1689-1694. PubMed ID: 29986909
[TBL] [Abstract][Full Text] [Related]
31. CD200 Expression in Neuroendocrine Neoplasms.
Love JE; Thompson K; Kilgore MR; Westerhoff M; Murphy CE; Papanicolau-Sengos A; McCormick KA; Shankaran V; Vandeven N; Miller F; Blom A; Nghiem PT; Kussick SJ
Am J Clin Pathol; 2017 Sep; 148(3):236-242. PubMed ID: 28821198
[TBL] [Abstract][Full Text] [Related]
32. Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?
Rosenblatt J; Avigan D
Blood; 2017 Jan; 129(3):275-279. PubMed ID: 27919908
[TBL] [Abstract][Full Text] [Related]
33. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site.
Zelle-Rieser C; Thangavadivel S; Biedermann R; Brunner A; Stoitzner P; Willenbacher E; Greil R; Jöhrer K
J Hematol Oncol; 2016 Nov; 9(1):116. PubMed ID: 27809856
[TBL] [Abstract][Full Text] [Related]
34. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
Lesokhin AM; Ansell SM; Armand P; Scott EC; Halwani A; Gutierrez M; Millenson MM; Cohen AD; Schuster SJ; Lebovic D; Dhodapkar M; Avigan D; Chapuy B; Ligon AH; Freeman GJ; Rodig SJ; Cattry D; Zhu L; Grosso JF; Bradley Garelik MB; Shipp MA; Borrello I; Timmerman J
J Clin Oncol; 2016 Aug; 34(23):2698-704. PubMed ID: 27269947
[TBL] [Abstract][Full Text] [Related]
35. Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade.
Suen H; Brown R; Yang S; Weatherburn C; Ho PJ; Woodland N; Nassif N; Barbaro P; Bryant C; Hart D; Gibson J; Joshua D
Leukemia; 2016 Aug; 30(8):1716-24. PubMed ID: 27102208
[TBL] [Abstract][Full Text] [Related]
36. Upregulation of CD200 is associated with regulatory T cell expansion and disease progression in multiple myeloma.
Aref S; Azmy E; El-Gilany AH
Hematol Oncol; 2017 Mar; 35(1):51-57. PubMed ID: 26033514
[TBL] [Abstract][Full Text] [Related]
37. CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy.
Moertel CL; Xia J; LaRue R; Waldron NN; Andersen BM; Prins RM; Okada H; Donson AM; Foreman NK; Hunt MA; Pennell CA; Olin MR
J Immunother Cancer; 2014; 2(1):46. PubMed ID: 25598973
[TBL] [Abstract][Full Text] [Related]
38. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells.
Coles SJ; Hills RK; Wang EC; Burnett AK; Man S; Darley RL; Tonks A
Leukemia; 2012 Sep; 26(9):2146-8. PubMed ID: 22430636
[No Abstract] [Full Text] [Related]
39. Lowering the threshold of lung innate immune cell activation alters susceptibility to secondary bacterial superinfection.
Goulding J; Godlee A; Vekaria S; Hilty M; Snelgrove R; Hussell T
J Infect Dis; 2011 Oct; 204(7):1086-94. PubMed ID: 21881124
[TBL] [Abstract][Full Text] [Related]
40. Variations in suppressor molecule ctla-4 gene are related to susceptibility to multiple myeloma in a polish population.
Karabon L; Pawlak-Adamska E; Tomkiewicz A; Jedynak A; Kielbinski M; Woszczyk D; Potoczek S; Jonkisz A; Kuliczkowski K; Frydecka I
Pathol Oncol Res; 2012 Apr; 18(2):219-26. PubMed ID: 21744007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
